Spero Therapeutics, Inc. (NASDAQ:SPRO) Receives Average Recommendation of “Hold” from Brokerages

Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Rating) has earned a consensus rating of “Hold” from the seven ratings firms that are presently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $37.33.

A number of analysts have recently weighed in on the stock. HC Wainwright dropped their target price on shares of Spero Therapeutics from $43.00 to $37.00 and set a “buy” rating for the company in a report on Monday, April 18th. Zacks Investment Research lowered shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, April 5th. Cantor Fitzgerald lowered their price objective on shares of Spero Therapeutics from $27.00 to $5.00 in a report on Tuesday. Berenberg Bank downgraded shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday. Finally, Cowen downgraded shares of Spero Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 4th.

Spero Therapeutics stock opened at $1.44 on Friday. The firm has a 50-day moving average of $5.64 and a 200-day moving average of $10.34. The firm has a market cap of $47.26 million, a P/E ratio of -0.44 and a beta of 1.87. Spero Therapeutics has a 1-year low of $1.38 and a 1-year high of $19.87.

Spero Therapeutics (NASDAQ:SPRO – Get Rating) last posted its earnings results on Monday, May 16th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.14). Spero Therapeutics had a negative return on equity of 116.93% and a negative net margin of 792.03%. During the same quarter in the previous year, the business earned ($0.66) EPS. Sell-side analysts anticipate that Spero Therapeutics will post -2.8 earnings per share for the current year.

In related news, major shareholder Aquilo Capital Management, Llc bought 39,727 shares of the business’s stock in a transaction on Tuesday, April 26th. The stock was acquired at an average price of $5.24 per share, with a total value of $208,169.48. Following the transaction, the insider now owns 5,321,231 shares in the company, valued at approximately $27,883,250.44. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 13.45% of the company’s stock.

A number of large investors have recently bought and sold shares of SPRO. Marshall Wace LLP bought a new stake in Spero Therapeutics in the 1st quarter worth approximately $39,000. Patriot Financial Group Insurance Agency LLC bought a new stake in Spero Therapeutics in the 4th quarter worth approximately $66,000. BNP Paribas Arbitrage SA grew its position in Spero Therapeutics by 358.6% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 4,343 shares of the company’s stock worth $80,000 after purchasing an additional 3,396 shares during the period. Engineers Gate Manager LP purchased a new position in shares of Spero Therapeutics during the 1st quarter worth $95,000. Finally, XTX Topco Ltd purchased a new position in shares of Spero Therapeutics during the 1st quarter worth $115,000. 69.36% of the stock is owned by institutional investors and hedge funds.

About Spero Therapeutics (Get Rating)

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease.

Read More